Canada 1st to receive DC Bead LUMI liver cancer treatment: 4 things to know

Ottawa, Canada-based BTG International Canada launched its DC Bead LUMI device in Canada on Dec. 5.

Advertisement

Here’s what you need to know.

1. The DC Bead LUMI is a radiopaque embolic drug-eluting bead that can have doxorubicin loaded into it to treat hepatocellular carcinoma or irinotecan for treating malignant colorectal cancer.

2. The DC Bead LUMI is the next iteration of the DC Bead which BTG says is the market leading drug-eluting embolic bead.

3. The new model allows for real-time confirmation of the devices location throughout embolization.

4. Sunnybrook Health Sciences Centre in Toronto, Canada, performed the first procedure with the new device.

More articles on gastroenterology/endoscopy:
AGA releases animated video for GERD education: 3 highlights
Invendo receives CE Mark for sterile, single-use endoscope: 5 things you need to know
Allergan settles with Zydus and Cadila over Delzicol: 4 things to know

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in GI & Endoscopy

Advertisement

Comments are closed.